The Oncology Institute, Inc. (TOI) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Medical - Care Facilities
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
N/A
—
5yr avg: 4.09
30Y Low1.1·High22.7
ROE
↓
N/A
—
5yr avg: -80.5%
30Y Low-213%·High0%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TOI Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
The Oncology Institute, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $5.4B | $3.3B | $23M | $150M | $133M | $646M | $638M | — |
| Enterprise Value | $5.5B | $3.4B | $97M | $237M | $227M | $532M | $644M | — |
| P/E Ratio → | -9.83 | — | — | — | — | — | — | — |
| P/S Ratio | 10.75 | 6.54 | 0.06 | 0.46 | 0.53 | 3.18 | 3.40 | — |
| P/B Ratio | — | — | 6.46 | 2.64 | 1.08 | 6.20 | 22.72 | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | 1256.83 | — |
P/E links to full P/E history page with 30-year chart
TOI EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.68 | 0.25 | 0.73 | 0.90 | 2.62 | 3.44 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
TOI Profitability
Margins and return-on-capital ratios measuring operating efficiency
The Oncology Institute, Inc. earns an operating margin of -7.2%. Operating margins have expanded from -23.8% to -7.2% over the past 3 years, signaling improving operational efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 15.2% | 15.2% | 13.7% | 18.4% | 20.6% | 20.1% | 19.7% | 19.3% |
| Operating Margin | -7.2% | -7.2% | -15.3% | -23.8% | -32.5% | -22.6% | -4.4% | -1.7% |
| Net Profit Margin | -12.1% | -12.1% | -16.4% | -25.6% | 0.1% | -5.4% | -7.6% | -2.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -213.4% | -92.2% | 0.1% | -16.5% | -40.7% | -9.5% |
| ROA | -35.9% | -35.9% | -33.9% | -35.3% | 0.1% | -8.1% | -22.9% | -6.8% |
| ROIC | -41.2% | -41.2% | -40.9% | -32.0% | -59.3% | -285.7% | -16.7% | -5.0% |
| ROCE | -33.7% | -33.7% | -40.8% | -37.9% | -40.4% | -43.5% | -19.7% | -5.8% |
TOI Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $70M ($104M total debt minus $34M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 34.31 | 2.10 | 0.88 | 0.00 | 0.42 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | 20.47 | 1.51 | 0.76 | -1.10 | 0.21 | -0.06 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | -8.23 |
| Debt / FCF | — | — | — | — | — | — | — | -1.01 |
| Interest Coverage | -4.39 | -4.39 | -8.02 | -8.88 | -17.64 | -141.82 | -41.69 | -780.67 |
TOI Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.59x means The Oncology Institute, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 4.12x to 1.59x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.59 | 1.59 | 2.15 | 4.12 | 4.39 | 5.17 | 1.04 | 1.60 |
| Quick Ratio | 1.35 | 1.35 | 1.96 | 3.73 | 4.08 | 4.95 | 0.89 | 1.32 |
| Cash Ratio | 0.47 | 0.47 | 0.95 | 2.38 | 2.48 | 3.84 | 0.21 | 0.18 |
| Asset Turnover | — | 3.05 | 2.28 | 1.55 | 0.96 | 1.00 | 2.85 | 2.61 |
| Inventory Turnover | 25.26 | 25.26 | 33.81 | 19.35 | 21.64 | 25.19 | 34.60 | 32.26 |
| Days Sales Outstanding | — | 43.07 | 45.17 | 48.31 | 58.45 | 38.20 | 33.59 | 34.61 |
TOI Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
The Oncology Institute, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.7% | 6.8% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.7% | 6.8% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $924M | $75M | $74M | $81M | $66M | $59M | $64M |
Peer Comparison
Compare TOI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TOIYou | $5B | -9.8 | — | — | 15.2% | -7.2% | — | -41.2% | — |
 AIOT | $574M | -9.8 | 51.2 | — | 53.7% | -7.1% | -17.7% | -4.3% | 18.1 |
 ONCO | $653669 | -0.2 | — | — | 77.6% | -778.2% | -110.6% | -32.8% | — |
 USPH | $999M | 46.2 | 13.5 | 16.4 | 20.1% | 10.3% | 2.0% | 5.6% | 4.1 |
 OPCH | $3B | 16.3 | 7.4 | 12.6 | 18.1% | 6.0% | 15.2% | 15.3% | — |
 ADUS | $2B | 17.9 | 12.0 | 16.8 | 32.5% | 9.7% | 9.3% | 8.8% | 1.3 |
 AMSF | $593M | 12.8 | 8.9 | 66.4 | 46.4% | 18.6% | 18.5% | 21.9% | 0.0 |
 MCK | $94B | 20.4 | 13.8 | 16.5 | 3.6% | 1.6% | — | 254.1% | 1.2 |
 CAH | $53B | 34.7 | 19.0 | 28.5 | 3.7% | 1.0% | — | 3378.7% | 3.0 |
 VEEV | $26B | 29.3 | 20.6 | 18.7 | 75.5% | 28.7% | 13.9% | 12.9% | 0.1 |
 DOCS | $4B | 20.4 | 16.5 | — | 89.1% | 33.3% | 19.3% | 19.8% | 0.0 |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
What if you invested $1,000 in TOI 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in TOI be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs TOI Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationTOI vs AIOT — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs PowerFleet, Inc..
Compare NowTOI — Frequently Asked Questions
Quick answers to the most common questions about buying TOI stock.
What is The Oncology Institute, Inc.'s P/E ratio?
The Oncology Institute, Inc.'s current P/E ratio is -9.8x. This places it at the 50th percentile of its historical range.
Is TOI stock overvalued?
Based on historical data, The Oncology Institute, Inc. is trading at a P/E of -9.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are The Oncology Institute, Inc.'s profit margins?
The Oncology Institute, Inc. has 15.2% gross margin and -7.2% operating margin.